209 results on '"Zlotta A.R."'
Search Results
2. Development and external validation of an artificial intelligence-based tool for PROGression Risk assessment in Non-muscle invasive Bladder Cancer (PROGRxN-BCa)
3. Temporal validation of an artificial intelligence tool (SEPERA) to inform nerve-sparing strategy during radical prostatectomy and comparison against urologists
4. Proportion of Gleason 8-10 prostate cancer found on biopsy and tumor aggressiveness in matched cohorts of men in Asia and Western countries
5. Risk of upper tract urothelial carcinoma recurrence following non-muscle invasive bladder cancer: A retrospective, multi-institutional analysis of 3,036 patients
6. Stenting versus nephrostomy tubes for bladder cancer associated with hydronephrosis: Does stenting increase the incidence of upper tract urothelial carcinoma by retrograde tumor cell seeding?
7. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum
8. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
9. Development, multi-institutional external validation, and algorithmic audit of SEPERA – An artificial intelligence-based side-specific extra-prostatic extension risk assessment tool for patients undergoing radical prostatectomy
10. Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum
11. O3 - Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum
12. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum
13. Propensity matched comparison of radical cystectomy with trimodality therapy for muscle invasive bladder cancer (MIBC): A multi-institutional study
14. Risk of genitourinary malignancies in Lynch syndrome patients with DNA mismatch repair gene mutations in a large Canadian Familial Registry
15. The genomic landscape of unsuspected, incidentally detected Gleason 7 prostate cancer found on autopsy
16. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
17. 4 - Development, multi-institutional external validation, and algorithmic audit of SEPERA – An artificial intelligence-based side-specific extra-prostatic extension risk assessment tool for patients undergoing radical prostatectomy
18. P119 - Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019?
19. Differences in contemporary biopsy Gleason score distribution in large cohorts of men diagnosed with prostate cancer from China and Canada
20. Contributors
21. Germline variation at 8q24 and prostate cancer risk in men of European ancestry.
22. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1).
23. Treatment options after failure of local curative treatments in prostate cancer: a controversial issue
24. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019?
25. FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?
26. Predicting post-operative complications in radical cystectomy patients using pre-operative CT-measured adipose tissue indices
27. A non-invasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade
28. The effect of lifestyle changes on serum PSA levels in a cohort of asymptomatic men with PSA between 2-10 ng/ml and normal DRE
29. Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study
30. Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
31. 3 Een nieuw systeem voor het substadiëren van T1-urotheelcelcarcinoom van de blaas: een prognostische analyse
32. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.
33. Nutrition and prostate cancer: evidence or suspicion?
34. Molecular tumour grading and classification of non muscle invasive bladder cancer based on whole transcriptome analysis
35. PT109 - The effect of lifestyle changes on serum PSA levels in a cohort of asymptomatic men with PSA between 2-10 ng/ml and normal DRE
36. 1074 - FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?
37. 981 - Predicting post-operative complications in radical cystectomy patients using pre-operative CT-measured adipose tissue indices
38. 614 - Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study
39. 236 - A non-invasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade
40. A1295 - Inverse probability treatment weighting comparison of radical cystectomy to trimodality therapy for cT2-cT4 muscle invasive bladder cancer.
41. 746 Molecular tumour grading of non muscle invasive bladder cancer based on whole transcriptome analysis
42. Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy
43. 422 TERT promoter methylation is a pan-cancer biomarker with prognostic significance in prostate cancer patients
44. 423 Functional role of the kallikrein 6 region of the kallikrein locus in genetic predisposition for aggressive (Gleason ≥8) prostate cancer: Fine-mapping and methylation study in a Canadian cohort and the Swiss arm of the European Randomized Study for Prostate Cancer Screening
45. 755 A five-gene DNA-methylation biomarker panel sensitively detects bladder cancer and discriminates between high-grade and low-grade disease in voided urine
46. 20 Creation of the Toronto Biopsy Avoidance Tools (T-BAT) with clinical parameter-only and adipokine biomarker-augmented versions
47. 128 - Molecular tumour grading and classification of non muscle invasive bladder cancer based on whole transcriptome analysis
48. 852 Prostate biopsy trends in relation to U.S. Preventative Task for recommendations against routine PSA-based screening: A time-series analysis
49. 793 A multidisciplinary bladder cancer clinic delivers personalized care for complex bladder cancer patients
50. 206 Fine-mapping of the Kallikrein region and its role in prostate cancer aggressiveness: Results from a Canadian cohort and the European Randomized Study for Prostate Cancer Screening
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.